![Page 1: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/1.jpg)
Research in Neurosciences,
A European Perspective
Peter Paul De DeynScientific Director Institute Born-Bunge
![Page 2: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/2.jpg)
![Page 3: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/3.jpg)
![Page 4: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/4.jpg)
The Network of European Neuroscience Schools (NENS) was founded in 2003 and represents over 150 of those graduate schools and programmes across ca. 30 European countries that offer Masters, MD, PhD and doctoral degrees in neuroscience. NENS is a formal structure within the Federation of European Neuroscience Societies (FENS).
The Network of European Neuroscience Schools
![Page 5: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/5.jpg)
The Network of European Neuroscience Schools (NENS) was founded in 2003 and represents over 150 of those graduate schools and programmes across ca. 30 European countries that offer Masters, MD, PhD and doctoral degrees in neuroscience. NENS is a formal structure within the Federation of European Neuroscience Societies (FENS).
The Network of European Neuroscience Schools
![Page 6: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/6.jpg)
European network for interdisciplinary discussions of the social implications of the neurosciences. Funded by the European Science Foundation
European Neuroscience and Society Network
![Page 7: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/7.jpg)
The Network of European Neuroscience Schools (NENS) was founded in 2003 and represents over 150 of those graduate schools and programmes across ca. 30 European countries that offer Masters, MD, PhD and doctoral degrees in neuroscience. NENS is a formal structure within the Federation of European Neuroscience Societies (FENS).
The Network of European Neuroscience Schools
![Page 8: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/8.jpg)
The Network of European Neuroscience Schools
![Page 9: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/9.jpg)
Publication Analysis 1997-2008Clinical Neurosciences
![Page 10: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/10.jpg)
![Page 11: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/11.jpg)
![Page 12: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/12.jpg)
The strategic guidance for our funding of brain research is the 7th Framework Programme on Research and Technical Development (FP7) implemented through so-called Specific Programmes (SPs). Health research in general and brain research in particular is implemented in the Specific Programme Cooperation. Support for infrastructures is provided through the Specific Programme Capacities. The well-established Marie-Curie fellowships are funded through the Specific Programme People and the European Research Council is funded through the Specific Programme Ideas.
European Commission – Health Research - Brain Research
![Page 13: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/13.jpg)
Brain research is supported in the Seventh Framework Programme (FP7; 2007-2013), which includes an activity on ‘Research on the brain and related diseases’ under the theme ‘Health’. This activity has a particular emphasis on translational research, meaning translation of basic discoveries into clinical applications. In the first three FP7 calls, 30 projects were funded under this activity for a total of EUR 135 million. Research relevant to the brain and the nervous system is also addressed in other areas of the current ‘Health’ theme, where an additional 49 research projects received funding for about EUR 247 million.
European Commission – Health Research - Brain Research
![Page 14: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/14.jpg)
Promoting Breakthrough Therapies
across EuropeMichel Goldman, MD,PhD
Executive Director
Belgian Brain Congress 2010
![Page 15: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/15.jpg)
Innovative Medicines Initiative:the Largest PPP in Life Sciences R&D
2 Billion Euro
1 Billion €1 Billion €
Public PrivatePartnership
![Page 16: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/16.jpg)
IMI: Topics for the First Call
1. Improved predictivity of immunogenicity 13m/ 5y 2. Non-genotoxic carcinogenesis 2.5m/2y plus 10m/ 3y 3. Expert systems for in silico toxicity prediction 5m/ 5y4. Improved predictivity of non-clinical safety evaluation 10m/ 3y 5. Qualification of Translational safety biomarkers 21m/ 5y6. Strengthening the monitoring of benefit/risk 15m/ 5y7. Islet cell research 10m/ 5y8. Surrogate markers for vascular endpoints 20m/ 5y9. Pain research 7.5m/ 5y10. New tools to develop novel therapies in psychiatric disorders 10m/ 5y11. Neurodegenerative disorders 7.5m/ 5y12. Understanding severe asthma 12.5m/ 5y13. COPD Patient Reported Outcomes 2m/ 1y + 8m/5y14. European Medicines Research Training Network 5m/ 7yn Safety sciences for medicines training programme 3m/ 5y1. Pharmaceutical medicine training programme 4m/ 5y2. Integrated medicines development training programme 3m/ 5y3. Pharmacovigilance training programme 3.5m/ 5y
EFPIA Commitment: 172.5m Euros, typical project ~15m, 5-10 EFPIA partners/project, majority of 5y duration
![Page 17: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/17.jpg)
IMI: Neurodegenerative Disorders
Bridging the preclinical /clinical
Clinical outcome studies in the neurodegeneration area are notoriously long and expensive. In order to accelerate the successful development of molecules for the treatment of Neurodegenerative disorders, it is essential to improve the predictive value of animal models, identify pharmacodynamic markers of drug response, pharmacodynamic models that allow early prediction of efficacy and markers to aid stratification of the patient population. The success of this will be dependent on the partnership of preclinical and clinical scientists to adopt an integrated approach to ensure effective translation of efficacy from bench to bedside andvisa versa. This translational science/medicine approach will allow the rapid identification and accelerated development of successful candidate molecules as well as terminating efforts earlier on those unlikely to offer clinical benefit.
![Page 18: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/18.jpg)
IMI Projects on Brain Disorders
Alzheimer’s diseasePilot project: Addneuromed
Ongoing project: Pharmacog (total budget: 27.7 M €)
Schizophrenia and depressionOngoing project: Newmeds (total budget: 24.0 M €)
Autism Call for Proposals to be released end October 2010
![Page 19: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/19.jpg)
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development.
PHARMA-COG
![Page 20: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/20.jpg)
Area 4.2 - Support to policies
HEALTH-2010.4.2-8: Coordination action in support of the implementation by participating States of a Joint Programming Initiative for combating neurodegenerative diseases, in particular Alzheimer's disease. Following the Commission's Communication on Joint Programming to tackle Europe's major societal challenges, the Competitiveness Council, called for a common commitment of EU Member States (MS) to fight Alzheimer's disease and other neurodegenerative diseases. The successful coordination action must support the implementation of a pilot Joint Programming Initiative by proposing innovative ways of pooling national expertise and resources and establishing closer and robust collaborations among the participating States in the field of neurodegenerative diseases, in particular Alzheimer's disease. Applicants must be national/regional agencies and/or ministries funding activities related to neurodegenerative diseases.
Funding scheme: Coordination and Support Action (Coordinating Action).
Description and scope of topic 4.2-8:
![Page 21: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/21.jpg)
The European Brain Council (EBC), established in 2002, involves all major European organizations involved in brain-related issues ranging from scientific and clinical societies, to industry and patients organizations. EBC - together with its member organizations – promotes brain research in Europe; this will lead to new therapeutic and diagnostic tools and together with improved education and information. An important goal is to improve the quality of life of those European citizens living with brain-related diseases as well as of their carers.
![Page 22: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/22.jpg)
I: Development, plasticity & ageing of the brain in health & disease II. Mind – brain relationship and mental disorders III. Degeneration & repair in the Brain IV. Revealing pain mechanisms & their control V. Rehabilitation, psychological care & prevention VI. Sensory systems & autonomic disturbances VII. Towards a better diagnostic & therapeutic approach: enabling technologies
![Page 23: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/23.jpg)
Vision UA
![Page 24: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/24.jpg)
Institute Born-Bunge
Institute Bunge (clinic and research) : 1934-1962-1979
“.. In order to establish a center for surgical and medical research where full diagnostic research could be combined with scientific research.”
Travaux de l’Institut Bunge Vol I, 1936. Born-Bunge Foundation (research) :
1963-2004 Institute Born-Bunge (research) :
from 2005
![Page 25: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/25.jpg)
Ludo van Bogaert and Charles Poser 1955
![Page 26: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/26.jpg)
![Page 27: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/27.jpg)
Prof. Armand Lowenthal1919-2001Intrathecal IgG synthesis in MS
Micro-Eletrophoresis in Agar Gel of Proteins of the Cerebrospinal Fluid and Central Nervous System 1959. D. Karcher, M. van Sande and A. Lowenthal. Institute of Tropical Medicine, Antwerp, and Institute Bunge, Berchem Antwerp, Belgium Journal of Biochemistry 1959; 4: 135-140
![Page 28: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/28.jpg)
Prof. Armand Lowenthal
![Page 29: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/29.jpg)
Prof. J.J. Martin
Neurometabolic storage diseases (together with Prof. Ceuterick-De Groote)Neuromuscular disordersDetailed anatomical study of the thalamusNeuropathological study of dementia
![Page 30: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/30.jpg)
Brief presentation IBB Laboratories and groups
![Page 31: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/31.jpg)
Laboratory for Electrobiology
![Page 32: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/32.jpg)
Laboratory for Neurobiology
![Page 33: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/33.jpg)
Laboratory for Theoretical Neurobiology
En: Ongoing research on the physiology of brain-computer interfaces
![Page 34: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/34.jpg)
Laboratory for Neurochemistry & Behaviour
![Page 35: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/35.jpg)
Laboratory for Neurochemistry & Behaviour
![Page 36: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/36.jpg)
Laboratory for Neurochemistry & Behaviour
Reference for Biological Markers of Memory disorders
![Page 37: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/37.jpg)
LNG: Behavioural research and pharmacological modulation in rodent models of dementia
Van Dam D. & De Deyn P.P. Drug development in dementia: the role of rodent models. Nature Reviews Drug Discovery (2006)
![Page 38: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/38.jpg)
IBB- Laboratories for Neurogenetics
Three research groups active in the investigation of complex neurological diseases of the peripheral and central nervous system
Peripheral Neuropathies Vincent Timmerman
Neurogenetics Peter De Jonghe
Neurodegenerative Brain diseases Christine Van Broeckhoven
![Page 39: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/39.jpg)
Peripheral Neuropathy group
About nerves, pedigrees and genes
![Page 40: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/40.jpg)
Neurogenetics group
![Page 41: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/41.jpg)
IBB- Neurodegenerative Brain diseases Group
![Page 42: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/42.jpg)
Frontotemporal Dementia with Ubiquitin-positive inclusions
Key publications Cruts,M., Gijselinck,I., van der Zee,J., Engelborghs,S., Wils,H., Pirici,D., Rademakers, R.,
Vandenberghe,R., Dermaut,B.,Martin,J-J., van Duijn,C., Peeters,K., Sciot,R., Santens,P., De Pooter,T., Mattheijssens,M., Van den Broeck,M.,Cuijt,I.,Vennekens,K., De Deyn,P.P, Kumar-Singh,S., Van Broeckhoven,C. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21, Nature, 442(7105):920-924 (2006)
van der Zee,J., Rademakers,R., Engelborghs,S., Gijselinck,I., Bogaerts,V., Vandenberghe,R., Santens,P., Caekebeke,J., De Pooter,T., Peeters,K., Lübke,U., Van den Broeck,M., Martin,J-J., Cruts,M., De Deyn,P.P., Van Broeckhoven,C., Dermaut,B.: A Belgian Ancestral Haplotype Harbors a Highly Prevalent mutation for 17q21-Linked Tau-negative FTLD. Brain 129(4): 841-852 (2006)
Pirici,D., van der Zee,J., Vandenberghe,R., Rademakers,R., Dermaut,B., Cruts,M., Vennekens,K., Cuijt,I., Lübke,U., Ceuterick,C., Martin,J-J., Van Broeckhoven,C., Kumar-Singh,S.: Characterization of ubiquitinated intraneural inclusions in a novel Belgian FTLD family. Journal of Neuropathology & Experimental Neurology 65(3): 289-301 (2006)
IBB- Neurodegenerative Brain diseases Group
![Page 43: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/43.jpg)
FTDU-17 gene is progranulin
PGRN is located at 17q21.32, 1.7 Mb centromeric of MAPT
Growth modulatory activity Role in several physiological and pathological
processes (development, wound repair, inflammation and tumorigenesis)
Cysteine-rich polypeptide7.5 x 12-cysteine granulin motif
Function in brain?
gDNA0 1 2 3 4 5 6 7 8 9 10 11 12
UTR
UTR P G F B A C D E mRNA593 codons
Baker et al. and Cruts et al. Nature 2006
![Page 44: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/44.jpg)
Laboratory for Ultrastructural neuropathology & Biobank
![Page 45: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/45.jpg)
IBB BIOBANKCo-ordinator: PP De Deyn
BrainNeuromuscular specimens / skin
Cerebrospinal fluidBlood - plasma - serum
DNA, Cell culturesHuman & animal
Task Forces
Neuromuscular Disorders
Responsible: C. CeuterickP. De Jonghe/ V. TimmermanK. Claeys, L. HeytensConsultant: J.J. Martin(NMRC UZA, LUN)
TF 1
Prion Diseases
Responsible: P. Cras
(Lab. of Neurobiology)
TF 2 CNS NeurodegenerativeDisorders (dementia/park)Responsibles: C. Van Broeckhoven &PP. De Deyn
S. EngelborghsS. Kumar-SinghConsultant: J.J. Martin(LNG, LNB)
TF 3
![Page 46: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/46.jpg)
Impact factors of IBB publications in 2009
IBB Publications 2009
impact factors
no IF 0-2 2-4 4-6 6-8 8-10 > 10
nu
mb
er
of
pu
blic
atio
ns
0
5
10
15
20
25
30
35 published (n=78)in press (n=14)
total n=92
![Page 47: Research in Neurosciences, A European Perspective](https://reader036.vdocument.in/reader036/viewer/2022062323/568159e3550346895dc72ee4/html5/thumbnails/47.jpg)